Cardiology
Conference Coverage
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early...
From the Journals
Early hypertensive disorders in pregnancy linked to obesity
An analysis from a large U.S. database has enough power to demonstrate link between obesity and rare early-onset hypertensive disorder.
News from the FDA/CDC
ED visits for life-threatening conditions declined early in COVID-19 pandemic
Visits for MI, stroke, and hypoglycemic crisis dropped 10%-23% over the first 10 weeks.
Conference Coverage
T2D plus heart failure packs a deadly punch
Medical records from 150,000 Danish patients with type 2 diabetes showed heart failure comorbidity was the deadliest combination.
Feature
Cost of preventable adult hospital stays topped $33 billion in 2017
Heart failure, diabetes, and COPD were the most expensive preventable conditions.
News from the FDA/CDC
U.S. adults reach Healthy People 2020 cholesterol goal
From the Journals
CVD risk continues to fall down to systolic BP of 90 mm HG
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
Commentary
Preventing arrhythmias and QTc prolongation in COVID-19 patients on psychotropics
Psychotropics associated with QTc interval prolongation should be discontinued (or substituted with a low-risk agent) if a patient presents with...
Conference Coverage
Frequent hypoglycemic episodes raise cardiac event risk
It’s “essential” to avoid drugs associated with hypoglycemia to minimize CV event risk in patients with type 2 diabetes, investigator says.
Conference Coverage
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
Conference Coverage
Smart phones boosted compliance for cardiac device data transmission